ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer
Authors
Keywords
ARID1A, AT-rich interactive domain 1A, Ovarian cancer, Immune therapy, Immunotherapy, PD-L1
Journal
GYNECOLOGIC ONCOLOGY
Volume 162, Issue 3, Pages 679-685
Publisher
Elsevier BV
Online
2021-07-14
DOI
10.1016/j.ygyno.2021.07.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer
- (2021) Amir Mehrvarz Sarshekeh et al. CLINICAL CANCER RESEARCH
- Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
- (2021) Huijuan Ge et al. Diagnostic Pathology
- SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models
- (2020) Yemin Wang et al. Annual Review of Pathology-Mechanisms of Disease
- Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
- (2020) Shin Nishio et al. CANCER SCIENCE
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
- (2020) Richard C. Centore et al. TRENDS IN GENETICS
- Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors
- (2020) Keiko Saotome et al. Cancer Medicine
- Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
- (2020) Yu-Chien Lin et al. Journal of Ovarian Research
- Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer
- (2019) Young-Bae Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients
- (2019) Julia Maria Tober et al. HUMAN PATHOLOGY
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary
- (2015) Hiroaki Itamochi et al. International Journal of Clinical Oncology
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- ARID1A gene mutation in ovarian and endometrial cancers (Review)
- (2015) TAKASHI TAKEDA et al. ONCOLOGY REPORTS
- ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas
- (2013) Ghassan Allo et al. MODERN PATHOLOGY
- Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
- (2013) Tjalling Bosse et al. MODERN PATHOLOGY
- ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
- (2012) Jennifer N. Wu et al. Cancer Discovery
- ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
- (2011) B. Guan et al. CANCER RESEARCH
- Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers
- (2011) William J. Lowery et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
- (2011) Kai Wang et al. NATURE GENETICS
- PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma
- (2011) Sohei Yamamoto et al. VIRCHOWS ARCHIV
- Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
- (2010) Daichi Maeda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- The SWI/SNF complex and cancer
- (2009) D Reisman et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now